Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.

Tytuł:: Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective.
Autorzy:: Rufai SB; Division of Clinical Microbiology and Molecular Medicine, Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India.; Department of Microbiology, All India Institute of Medical Sciences, Bhopal, India.
Umay K; Department of Microbiology, All India Institute of Medical Sciences, Bhopal, India.
Singh PK; Department of Microbiology, All India Institute of Medical Sciences, Bhopal, India.
Singh S; Division of Clinical Microbiology and Molecular Medicine, Department of Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India.; Department of Microbiology, All India Institute of Medical Sciences, Bhopal, India.
Źródło:: PloS one [PLoS One] 2020 Mar 04; Vol. 15 (3), pp. e0229419. Date of Electronic Publication: 2020 Mar 04 (Print Publication: 2020).
Typ publikacji:: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:: Genotyping Techniques*
Drug Resistance, Bacterial/*genetics
Tuberculosis, Multidrug-Resistant/*genetics
Humans ; India ; Retrospective Studies
References:: Antimicrob Agents Chemother. 2016 Nov 21;60(12):7522-7523. (PMID: 27736762)
J Infect Public Health. 2018 Jan - Feb;11(1):54-58. (PMID: 28404233)
J Clin Microbiol. 2008 Dec;46(12):3952-6. (PMID: 18945838)
Sci Rep. 2018 Jun 18;8(1):9295. (PMID: 29915257)
BMC Infect Dis. 2013 May 24;13:240. (PMID: 23705640)
PLoS One. 2012;7(11):e49433. (PMID: 23166667)
J Clin Microbiol. 2018 May 25;56(6):. (PMID: 29563202)
J Mol Diagn. 2013 Jan;15(1):44-50. (PMID: 23159109)
J Clin Microbiol. 2012 Sep;50(9):2857-62. (PMID: 22649019)
J Clin Microbiol. 2010 Aug;48(8):2749-53. (PMID: 20554815)
PLoS One. 2015 Mar 27;10(3):e0120470. (PMID: 25816236)
Biomed Res Int. 2016;2016:2628913. (PMID: 27652260)
BMC Infect Dis. 2018 Jun 7;18(1):261. (PMID: 29879908)
J Clin Microbiol. 2010 Aug;48(8):2934-9. (PMID: 20573868)
J Clin Microbiol. 2012 Jan;50(1):30-6. (PMID: 22075597)
BMC Infect Dis. 2016 Oct 19;16(1):583. (PMID: 27756241)
Kekkaku. 2012 Oct;87(10):641-7. (PMID: 23214120)
J Clin Microbiol. 2010 May;48(5):1683-9. (PMID: 20335420)
Microbiol Resour Announc. 2019 Feb 14;8(7):. (PMID: 30801057)
Am J Respir Crit Care Med. 2016 Sep 1;194(5):621-30. (PMID: 26910495)
Clin Infect Dis. 2010 Jul 1;51(1):6-14. (PMID: 20504231)
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20004-9. (PMID: 19906990)
Int J Mycobacteriol. 2014 Mar;3(1):50-6. (PMID: 26786223)
Int J Tuberc Lung Dis. 2018 Apr 1;22(4):419-424. (PMID: 29562990)
Int J Tuberc Lung Dis. 2014 Feb;18(2):233-9. (PMID: 24429319)
Sci Rep. 2016 Feb 10;6:17850. (PMID: 26860462)
BMC Infect Dis. 2018 Feb 27;18(1):98. (PMID: 29486710)
J Clin Microbiol. 2016 Jun;54(6):1573-1580. (PMID: 27053671)
J Clin Microbiol. 2011 Jul;49(7):2502-8. (PMID: 21562102)
Lancet. 2009 May 30;373(9678):1861-73. (PMID: 19375159)
Tuberc Res Treat. 2013;2013:108401. (PMID: 23606961)
Eur Respir J. 2010 Sep;36(3):584-93. (PMID: 20185428)
J Clin Microbiol. 2017 Mar;55(3):791-800. (PMID: 27974543)
Antimicrob Agents Chemother. 2017 Aug 24;61(9):. (PMID: 28630205)
Entry Date(s):: Date Created: 20200305 Date Completed: 20200615 Latest Revision: 20231113
Update Code:: 20240105
PubMed Central ID:: PMC7055869
DOI:: 10.1371/journal.pone.0229419
PMID:: 32130233
: Czasopismo naukowe

Pełny tekst

Genotype MTBDRsl Version 1 (V1.0) was recommended as an initial test for rapid detection of pre-extensively drug resistant (pre-XDR) and extensively drug resistant tuberculosis (XDR-TB). However, in recent years a number of novel mutations are identified that confer resistance. Thus, Genotype MTBDRsl V2.0 was endorsed by WHO. Though, Genotype MTBDRsl V2.0 has been rolled out in national TB programme in 2018, there is dearth of data from India on its performance for second line drug susceptibility testing (DST). For this, performance of new version was evaluated on 113 MDR-TB isolates. The results showed that 39 (34.5%) of these isolates were resistant to FQ and 7 (6.2%) were XDR by Genotype MTBDRsl V2.0. Amongst the FQ resistant isolates most prevalent mutation was ΔWT3-D94G (17; 38.6%) and N538D (12; 85.7%). Among the AG/CP and KAN resistant isolates most common mutation in the rrs region was ΔWT1-A1401G (5; 71.4%) and C-14T (2; 28.5%) in eis gene. Second line Bactec MGIT-960 detected 40 (35.4%) isolates as resistant to FQ and 6 (5.3%) as XDR isolates, whereas Genotype MTBDRsl V1.0 also detected 39 (34.5%) as resistant to FQ but missed 2 isolates in correctly identifying as XDR (5; 4.4%). Thus, concordance of second line Bactec MGIT-960 with Genotype MTBDRsl V2.0 was similar (100%) for FQ detection but it has improvised the diagnostic sensitivity for correctly identifying XDR isolates. Nevertheless, the cost of Genotype MTBDRsl V2.0 remains an issue for screening of second line drug (SLDs) resistance from countries with high burden of MDR-TB.
Competing Interests: No author has competing interest.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja